CH7C4 is the first highly effective and selective HER2 degrader. Compared to traditional HER2-targeted drugs like Tucatinib, it completely degrades HER2, preventing drug resistance and inhibiting key oncogenic pathways (PI3K/AKT, RAS/RAF/ERK). Since some oral squamous cell carcinomas (OSCC) overexpress HER2, CH7C4 may effectively treat these tumors. Here, AKT1 is linked to oral cavity squamous cell carcinoma.